Research Evaluation of Safety and Impact in Long COVID Intervention with Ensitrelvir for National Cohort Efficacy (RESILIENCE study)

Some patients who have recovered from the acute phase of COVID-19 infection are experiencing various post-infection symptoms called Long COVID, such as respiratory and cardiovascular symptoms, taste and smell disorders, and neurological impairments, leading to a decreased quality of life (QOL) and impact on social life. The pathophysiology of these conditions is largely unknown, and there are no confirmed treatments or prevention methods. Shionogi Pharmaceutical is developing Ensitrelvir fumarate, a new oral antiviral drug that inhibits the 3C-like protease essential for the replication of SARS-CoV-2. This drug has the potential to address these social issues. Universities, with their specialized knowledge and medical infrastructure, are collaborating with industry to rapidly advance research aimed at elucidating the pathophysiology of Long COVID and establishing treatment and prevention methods.

Principal Investigator